Outlook Therapeutics, Inc.
LYTENAVA
neovascular age-related macular degeneration
Resolved
7days ago
Catalyst readout · Jun 30, 2026
What's at stake
A key catalyst for LYTENAVA (neovascular age-related macular degeneration) is expected Jun 30, 2026.
Primary source
· SEC 8-K
verified 14h ago
“The Company expects to resubmit the BLA in June 2026 as a Class 1 resubmission.”